title: Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China.
abstract: BACKGROUND
  Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL.
  
  
  METHODS
  120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed.
  
  
  RESULTS
  Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone.
  
  
  CONCLUSIONS
  Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival.
authors.affiliation: Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Liang
authors.forename: Zhe
authors.initials: Z
authors.lastname: Wang
authors.forename: Qing-Xian
authors.initials: QX
authors.lastname: Bai
authors.forename: Guang-Xun
authors.initials: GX
authors.lastname: Gao
authors.forename: Lan
authors.initials: L
authors.lastname: Yang
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Hong-Tao
authors.initials: HT
authors.lastname: Gu
authors.forename: Bao-Xia
authors.initials: BX
authors.lastname: Dong
authors.forename: Mi-Mi
authors.initials: MM
authors.lastname: Shu
authors.forename: Cai-Xia
authors.initials: CX
authors.lastname: Hao
authors.forename: Na
authors.initials: N
authors.lastname: Zhang
authors.forename: Xie-Qun
authors.initials: XQ
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D059248:Chemoradiotherapy / Q000401:mortality* / Q000706:statistics & numerical data; D002648:Child; D002681:China / Q000453:epidemiology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D015996:Survival Rate; D055815:Young Adult